Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation  Gita Thanarajasingam, Haesook T. Kim,

Slides:



Advertisements
Similar presentations
A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,
Advertisements

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD by Ana C. Alho, Haesook T.
A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.
Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome  Joseph Delano F. Robles, Daniel.
Cord-Blood Hematopoietic Stem Cell Transplant Confers an Increased Risk for Human Herpesvirus-6-Associated Acute Limbic Encephalitis: A Cohort Analysis 
How to Treat MDS without Stem Cell Transplantation
Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation 
Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation  Joseph H. Antin, Eva C. Guinan,
Biology of Blood and Marrow Transplantation
Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years  Areej El-Jawahri, Shuli Li, Joseph.
Allogeneic Stem Cell Transplantation in Myelofibrosis
Bradley W. Blaser, Haesook T. Kim, Edwin P. Alyea, Vincent T
Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury  Corey Cutler, Haesook T. Kim, Shaké Ayanian, Gary Bradwin, Carolyn Revta,
by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T
A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft- versus-Host Disease  Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra,
Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome  Philippe Armand,
Sabina Kersting, Leo F. Verdonck 
Betty T. Tran, Abigail Halperin, Jason W. Chien 
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.
Nienke M. G. Rorije, Margaret M. Shea, Gowri Satyanarayana, Sarah P
Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation  Joseph Pidala, Claudio.
Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.
Jennifer Crombie, Laura Spring, Shuli Li, Robert J. Soiffer, Joseph H
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation  Philippe Armand, Haesook T. Kim, Daniel.
Seroprotective Titers against 2009 H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Recipients  Nicolas.
Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation  Karen Ballen, Adam M. Mendizabal, Corey Cutler, Ioannis Politikos,
Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya.
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria  Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,
Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation  Lindsay G. Jensen, Tracey Stiller,
Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute.
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report.
Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome  Haesook T. Kim, Philippe Armand,
Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival  Priya Kumar, Todd E. Defor,
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.
Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis  Nicolas Novitzky, Valda.
Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease  Caron A. Jacobson, Lixian Sun, Haesook.
An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease 
Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma  Anuj Mahindra, Brian Bolwell, Ronald.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.
Mucositis after Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study of Methotrexate- and Non-Methotrexate-Containing Graft-versus-Host.
Allogeneic Stem Cell Transplantation for Aplastic Anemia
Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom  Haesook T. Kim, Philippe Armand  Biology of Blood.
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Akiko M. Saito, Corey Cutler, David Zahrieh, Robert J
Merve Postalcioglu, Haesook T. Kim, Faruk Obut, Benjamin C
Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease 
What is quality in a transplant program?
The Impact of Geographic Proximity to Transplant Center on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation  Karim E. Abou-Nassar, Haesook.
Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.
Philippe Armand, MD, PhD, Haesook T
Recovery of Circulating T-Follicular Helper Cells after Hematopoietic Stem Cell Transplantation  Edouard Forcade, MD, Steven Paula, Kristen Cowens, Marta.
Karen K. Ballen, Thomas R. Spitzer, Beow Y
Blood and Marrow Transplant Handbook
A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation  Philippe Armand, Haesook.
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation:
Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse 
John Koreth, Edwin P. Alyea, William J. Murphy, Lisbeth A. Welniak 
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Treatment versus Transplant for Challenging Hematologic Disorders
Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts  Yi-Bin Chen, Julie Aldridge,
Sarah Nikiforow, Haesook T
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation  Philippe Armand, Haesook T. Kim, Joanna Rhodes,
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation  Lindsey E.
Presentation transcript:

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation  Gita Thanarajasingam, Haesook T. Kim, Corey Cutler, Vincent T. Ho, John Koreth, Edwin P. Alyea, Joseph H. Antin, Robert J. Soiffer, Philippe Armand  Biology of Blood and Marrow Transplantation  Volume 19, Issue 12, Pages 1713-1718 (December 2013) DOI: 10.1016/j.bbmt.2013.09.011 Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 prOS stratified by risk score. (A) prOS in the main cohort of 351 patients. (B) prOS in a historical cohort of 276 patients. Biology of Blood and Marrow Transplantation 2013 19, 1713-1718DOI: (10.1016/j.bbmt.2013.09.011) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 prOS survival stratified by postrelapse treatment. Biology of Blood and Marrow Transplantation 2013 19, 1713-1718DOI: (10.1016/j.bbmt.2013.09.011) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions